ArticleTranslational cancer research2025
Integrative analysis of the potential of DISP3 as a biomarker for thyroid cancer.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid cancer (THCA) is a common endocrine malignancy with diverse prognostic outcomes. The role of dispatched RND transporter family member 3 (DISP3) in tumorigenesis remains unclear. This study aimed to investigate DISP3's biomarker potential in THCA. Methods: DISP3 expression in THCA and its correlation with clinicopathological features was analyzed from The Cancer Genome Atlas (TCGA) datasets. Functional enrichment, immune infiltration, genomic alterations and drug sensitivity analyses were performed. Prognostic value was evaluated by Kaplan-Meier analysis, Cox regression, and a nomogram that integrates DISP3 expression with key clinical variables. Results: DISP3 exhibited elevated expression levels in THCA tissues compared with normal thyroid tissues (P<0.001). Functional enrichment highlighted involvement in key biological processes and pathways, including the Hedgehog and Notch signaling pathways. DISP3 expression was positively correlated with cell cycle-related genes. Clinicopathological analysis indicated that high DISP3 expression was associated with female gender, N1 stage and poor overall survival (OS). Receiver operating characteristic (ROC) analysis demonstrated the diagnostic potential of DISP3 [area under the curve (AUC) =0.724]. Kaplan-Meier survival analysis confirmed that high DISP3 expression predicted poor prognosis for OS [hazard ratio (HR) =8.94]. A prognostic nomogram incorporating DISP3 expression and clinical factors showed substantial predictive accuracy (C-index: 0.818). DISP3 expression correlated with immune cell infiltration, particularly plasmacytoid dendritic cell (DC). DISP3 exhibited recurrent mutations (3.2%) and focal amplifications (11%), but promoter methylation was unchanged. High DISP3 correlated with sensitivity to PI3K/mTOR and Hedgehog inhibitors. Conclusions: DISP3 possibly serves as a potential biomarker for the diagnosis and prognosis of THCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.